Eiger BioPharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)

About Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. From an investor’s perspective, Eiger has historically been a rare-disease focused story built around highly targeted assets rather than a broad diversified platform. The company’s strategy centered on developing therapies for severe unmet-need conditions, initially around hepatitis delta virus (HDV) and later around select genetic and endocrine disorders. Eiger’s headquarters were in Palo Alto, California, placing it in one of the most established biotech clusters in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1305253/000130525323000005/eigr-20221231.htm?utm_source=openai)) Eiger’s core business model combined clinical development, regulatory execution, and, at times, commercialization of niche orphan-disease assets. Its best-known marketed product was Zokinvy® (lonafarnib), approved in the United States to reduce the risk of mortality in Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies. In January 2024, Eiger and partner AnGes also secured marketing approval for Zokinvy in Japan, underscoring the international dimension of the asset. In parallel, the company advanced avexitide, a first-in-class GLP-1 antagonist being developed for post-bariatric hypoglycemia and other forms of hyperinsulinemic hypoglycemia. That program attracted strategic interest from larger biotech buyers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1305253/000162828024015297/eigr-20231231.htm?utm_source=openai)) Competitively, Eiger was differentiated by focus rather than scale. The company operated in extremely narrow therapeutic niches where clinical and regulatory success can create meaningful value, but where dependence on a small number of programs also raises execution, financing, and concentration risk. This is a classic small-cap biotech profile: high optionality, but also high vulnerability to clinical setbacks, limited commercialization scale, and capital structure stress. Eiger’s recent history makes that risk profile particularly visible. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1305253/000119312524083560/d821503dnt10k.htm?utm_source=openai)) The most important recent developments occurred in 2024. On April 1, 2024, Eiger and its subsidiaries filed voluntary Chapter 11 petitions in the United States Bankruptcy Court for the Northern District of Texas. Following a court-supervised sale process, the company began monetizing key assets, including Zokinvy and avexitide, through transactions approved or announced during 2024. For equity analysts, that means Eiger should be viewed less as a conventional operating biotech and more as a restructuring and asset-monetization case, where residual value depends on legal outcomes, asset sales, and the treatment of stakeholders. Any assessment of the stock should therefore be framed around balance-sheet risk, bankruptcy proceedings, and the fate of remaining assets rather than a standard commercial-growth narrative. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001305253/000119312524083403/d818699dex991.htm?utm_source=openai))